No Picture
News

DTx Pharma Receives Prestigious Funding Award to Support Research in Neurodegenerative Diseases of the CNS

-DTx was one of 8 grantees selected out of more than 100 academic and company applicants worldwide-

SAN DIEGO, May 13, 2020 /PRNewswire/ — DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat … […]

No Picture
News

Cardiff Oncology Enters Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

– Funding will also enable the addition of new trial sites to accelerate completion of the Phase 2 clinical trial- Data continues to demonstrate the safety and efficacy of onvansertib as a promising new treatment for patients with KRAS-mutated mCRC

S… […]

No Picture
News

DelMar Pharmaceuticals Announces Fiscal Third Quarter 2020 Financial Results and Recent Corporate Updates

SAN DIEGO, May 13, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced its financial results for the thre… […]

No Picture
News

Viking Therapeutics Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting

SAN DIEGO, May 12, 2020 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced a change to it… […]

No Picture
News

Neurana Pharmaceuticals Announces Publication of a Driving Study Demonstrating the Effects of Tolperisone

SAN DIEGO, May 12, 2020 /PRNewswire/ — Neurana Pharmaceuticals, Inc., a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced the publication of a driving study which demonstrates the tolerabili… […]

No Picture
News

Halozyme Reports First Quarter 2020 Results

– DARZALEX FASPRO(TM) Utilizing ENHANZE® Technology Receives U.S. FDA Approval with Subcutaneous Administration Time of 3 – 5 Minutes and Lower Rate of Administration-related Reactions When Compared with IV DARZALEX® — Positive CHMP Opinion Recommendi… […]